Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …

Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

In Parkinson disease (PD), pathological processes and neurodegeneration begin long
before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's Disease (PD) is a common and progressive neurodegenerative disorder
characterised by motor impairments as well as non-motor symptoms. While dopamine …

Background Recent research on the implications of gut microbiota on brain functions has
helped to gather important information on the relationship between them. Pathogenesis of …

Alzheimer's disease is a devastating neurodegenerative disorder with no cure. Countless
promising therapeutics have shown efficacy in rodent Alzheimer's disease models yet failed …

It is generally thought that under basal conditions, neurons produce ATP mainly through
mitochondrial oxidative phosphorylation (OXPHOS), and glycolytic activity only …

Mutations in the E3 ubiquitin ligase parkin are the most common cause of early-onset
Parkinson's disease (PD). Although parkin modulates mitochondrial and endolysosomal …